Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zattoni

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
The Prostate|January 1, 1982
Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinomaA Veronesi, F Zattoni, S Frustaci, et al.
The Journal of Urology|May 20, 2008
Proposal of an improved prognostic classification for pT3 renal cell carcinomaC Terrone, P Gontero, A Volpe, et al.
European Urology|November 12, 2013
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]A Heidenreich, J Bellmunt, M Bolla, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]N Mottet, J Bellmunt, M Bolla, et al.
Letters in Applied Microbiology|February 11, 2022
Multiplexed flow cytometric approach for detection of anti-SARS-CoV-2 IgG, IgM and IgA using beads covalently coupled to the nucleocapsid proteinI F Zattoni, L F Huergo, E C M Gerhardt, et al.
Clinical Chemistry|December 4, 1998
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditionsM Gion, R Mione, P Barioli, et al.
The International Journal of Biological Markers|November 6, 1998
Prostate cancer probability after total PSA and percent free PSA determinationR Mione, P Barioli, M Barichello, et al.
European Urology|April 15, 2000
Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenarioM Gion, R Mione, P Barioli, et al.
Journal of Clinical Pathology|July 9, 2002
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancerC Selli, R Montironi, A Bono, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
The Prostate|January 1, 1982
Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinomaA Veronesi, F Zattoni, S Frustaci, et al.
The Journal of Urology|May 20, 2008
Proposal of an improved prognostic classification for pT3 renal cell carcinomaC Terrone, P Gontero, A Volpe, et al.
European Urology|November 12, 2013
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]A Heidenreich, J Bellmunt, M Bolla, et al.
Actas Urologicas Espanolas|July 16, 2011
[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]N Mottet, J Bellmunt, M Bolla, et al.
Letters in Applied Microbiology|February 11, 2022
Multiplexed flow cytometric approach for detection of anti-SARS-CoV-2 IgG, IgM and IgA using beads covalently coupled to the nucleocapsid proteinI F Zattoni, L F Huergo, E C M Gerhardt, et al.
Clinical Chemistry|December 4, 1998
Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditionsM Gion, R Mione, P Barioli, et al.
The International Journal of Biological Markers|November 6, 1998
Prostate cancer probability after total PSA and percent free PSA determinationR Mione, P Barioli, M Barichello, et al.
European Urology|April 15, 2000
Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenarioM Gion, R Mione, P Barioli, et al.
Journal of Clinical Pathology|July 9, 2002
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancerC Selli, R Montironi, A Bono, et al.
Pageof 9